Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia : Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Canakinumab on Cytokine Release Syndrome in Patients With COVID-19-induced Pneumonia (CAN-COVID)

This was a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of canakinumab plus standard-of-care (SOC) compared with placebo plus SOC in patients with COVID-19-induced pneumonia and cytokine release syndrome (CRS)..

Media Type:

Clinical Trial

Year of Publication:

2021

Publication:

2021

Contained In:

ClinicalTrials.gov - (2021) vom: 10. Juni To Main Record - year:2021

Language:

English

Links:

Volltext [Kostenfrei]

Keywords:

610
Medical Condition: Pneumonia and Cytokine Release Syndrome (Covid-19)
Phase: Phase 3
Pneumonia
Recruitment Status: Completed
Study Type: Interventional
Syndrome

Notes:

Source: Link to the current ClinicalTrials.gov record., First posted: April 27, 2020, Last downloaded: ClinicalTrials.gov processed this data on June 14, 2021, Last updated: June 15, 2021

NCTID:

04362813

Study Publications:

PPN (Catalogue-ID):

CTG003372200